Investor List:

Top Pharmaceuticals Series A Investors in London (33)

Know someone who's actively diligencing and investing? Add them to this list.

About this list

We’ve compiled a list of the top Pharmaceuticals investors. The goal is to help Founders find the best investors to target and get introduced to.

Photo of Alessandro Luciano, Vice President at Insight Partners

Alessandro Luciano

Insight Partners·Vice President

Sweet spot: $25.0M

Range: $10.0M - $350.0M

Investors in London

Investors in Education (Series B), Investors in Education (Series A), Investors in SMB Software (Series B), Investors in Pharmaceuticals (Series B), Investors in SMB Software (Series A), Investors in Health IT (Series A), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Series B), Investors in Health & Hospital Services (Series A), Investors in Education (Series A), Investors in Health IT (Series A), Investors in SMB Software (Series A), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Series A), Investors in Education (Series B), Investors in Health IT (Series B), Investors in Pharmaceuticals (Series B), Investors in Health & Hospital Services (Series B), Investors in SMB Software (Series B), Investors in London (Other Lists), Investors in Digital Health (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Digital Health (Series A)

to see your intro paths to Alessandro

Photo of Pablo Lubroth, Investor at Hummingbird Ventures

Hummingbird Ventures·Investor

Sweet spot: $2.8M

Range: $500K - $5.0M

Investors in London, Investors in New York (NY)

Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in New York City (Other Lists), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series B), Investors in London (Other Lists), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in DeepTech (Seed), Investors in DeepTech (Series A), Investors in DeepTech (Series B), Investors in DeepTech (Series A), Investors in DeepTech (Seed), Investors in DeepTech (Series B), Investors in DeepTech (Series A), Investors in DeepTech (Seed), Investors in Pharmaceuticals (Pre-seed), Investors in DeepTech (Series B), Investors in DeepTech (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Therapeutics (Series A), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in DeepTech (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Pre-seed), Investors in DeepTech (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Series B), Investors in BioTech (Pre-seed), Investors in Digital Health (Series A), Investors in Digital Health (Seed)

to see your intro paths to Pablo

Photo of Hussein Kanji, Analyst at Hoxton Ventures

Hoxton Ventures·Analyst

Sweet spot: $2.0M

Range: $1M - $3.0M

Investors in United Kingdom, Investors in London

Investors in Retail (Seed), Investors in Analytics (Series A), Investors in Pharmaceuticals (Seed), Investors in Security (Seed), Investors in Analytics (Seed), Investors in Retail (Series A), Investors in Security (Series A), Investors in AI (Seed), Investors in Diverse Investors (Other Lists), Investors in AI (Series A), Investors in Pharmaceuticals (Series A), Investors in Investors who were founders (Other Lists), Investors in Investors who invested in female founders (Other Lists), Investors in Analytics (Seed), Investors in Marketplaces (Series A), Investors in AI (Seed), Investors in Investors who invested in diverse founders (Other Lists), Investors in Consumer Internet (Seed), Investors in Marketplaces (Seed), Investors in Consumer Internet (Seed), Investors in Retail (Seed), Investors in SaaS (Seed), Investors in Security (Seed), Investors in Pharmaceuticals (Seed), Investors in AI (Series A), Investors in Analytics (Series A), Investors in Consumer Internet (Series A), Investors in Marketplaces (Series A), Investors in Retail (Series A), Investors in Security (Series A), Investors in SaaS (Series A), Investors in Pharmaceuticals (Series A), Investors in London (Other Lists), Investors in Angel, Scout, and Solo-Capitalists (Other Lists), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Enterprise Applications (Series A), Investors in Enterprise Applications (Seed), Investors in Enterprise Applications (Series A), Investors in Enterprise Applications (Seed), Investors in Pharmaceuticals (Pre-seed), Investors in Retail (Pre-seed), Investors in Analytics (Pre-seed), Investors in Security (Pre-seed), Investors in AI (Pre-seed), Investors in Enterprise Applications (Pre-seed), Investors in Digital Health (Pre-seed), Investors in AI (Pre-seed), Investors in Analytics (Pre-seed), Investors in Consumer Internet (Pre-seed), Investors in Marketplaces (Pre-seed), Investors in SaaS (Pre-seed), Investors in Security (Pre-seed), Investors in Marketplaces (Pre-seed), Investors in Retail (Pre-seed), Investors in SaaS (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Consumer Internet (Pre-seed), Investors in Enterprise Applications (Pre-seed), Investors in Digital Health (Pre-seed), Investors in SaaS (Series A), Investors in Consumer Internet (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Marketplaces (Seed), Investors in SaaS (Seed)

to see your intro paths to Hussein

Photo of Bali Muralidhar, Managing Partner at Abingworth

Bali Muralidhar

Abingworth·Managing Partner

Sweet spot: $22.5M

Range: $15.0M - $30.0M

Investors in London

Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Series A), Investors in London (Other Lists), Investors in Health IT (Seed), Investors in Health & Hospital Services (Seed)

to see your intro paths to Bali

Photo of Andrew Kozlov, Managing Partner at 4BIO Capital

4BIO Capital·Managing Partner

Sweet spot: $1.5M

Range: $100K - $5.0M

Investors in London

Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in London (Other Lists), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A)

to see your intro paths to Andrew

Photo of Shahzad Malik, General Partner at Advent Life Sciences

Advent Life Sciences·General Partner

Sweet spot: $1M

Range: $25K - $5.0M

Investors in London

Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in London (Other Lists), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B)

to see your intro paths to Shahzad

Photo of Robert Thong, General Partner at Selvedge Venture

Selvedge Venture·General Partner

Sweet spot: $1.5M

Range: $100K - $5.0M

Investors in London

Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series A), Investors in BioTech (Seed), Investors in Enterprise (Seed), Investors in Enterprise (Series A), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Series A), Investors in Enterprise (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Series A), Investors in London (Other Lists), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Enterprise Applications (Series A), Investors in Enterprise Applications (Seed), Investors in Enterprise Applications (Series A), Investors in Enterprise Applications (Seed), Investors in Pharmaceuticals (Pre-seed), Investors in Health IT (Pre-seed), Investors in Enterprise Applications (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Enterprise (Pre-seed), Investors in Enterprise (Pre-seed), Investors in Health IT (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Enterprise Applications (Pre-seed), Investors in BioTech (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Health IT (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in Enterprise (Seed)

to see your intro paths to Robert

Photo of Shu Joshi, Managing Partner at Life Science Vision (LSV) Capital

Life Science Vision (LSV) Capital·Managing Partner

Sweet spot: $1.5M

Range: $100K - $5.0M

Investors in London

Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series A), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Medical Devices (Series A), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Series A), Investors in London (Other Lists), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health IT (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)

to see your intro paths to Shu

Get new data & insights delivered to your inbox